An in-depth analysis of the efficacy and price of Tucatinib: New hope for patients with HER2-positive breast cancer

In recent years, the update and iteration of oncology drugs has been accelerating. Especially in the field of breast cancer, the research and development results of targeted therapy drugs have frequently appeared on the international academic stage. 2023Since HER2 positive breast cancer treatment has once again become a medical hot spot, and the research progress and price issues of the small molecule targeted drug Tucatinib (Tucatinib, trade name Tukysa) are arousing the attention of more and more patients and family members. This article will combine the latest medical information to systematically introduce the efficacy and price of tucatinib from multiple perspectives, providing valuable reference information for patients.

1. Latest medical hot spots and increased attention to tucatinib

In2023ASCO (American Society of Clinical Oncology Annual Meeting) and ESMO (European Society for Medical Oncology Congress), HER2 positive breast cancer treatment became a major topic. Among them, the HER2CLIMB study of tucatinib combined with trastuzumab and capecitabine has attracted global attention.

Research data show that tucatinib can significantly prolong progression-free survival (PFS) and overall survival (OS) in patients with HER2-positive metastatic breast cancer who have received multiple lines of treatment, especially those with brain metastases. This achievement is landmark for the large number of patients who face treatment difficulties due to brain metastases.

In addition, experts pointed out that HER2 positive breast cancer has urgent clinical needs after the failure of trastuzumab, pertuzumab and T-DM1 regimens. Tucatinib relies on its small molecule tyrosine kinase inhibitor (TKI) mechanism to penetrate the blood-brain barrier, bringing new treatment opportunities to patients with brain metastases.

2. The core efficacy advantages of tucatinib

1. Breakthroughs for patients with brain metastases

HER2CLIMBThe study confirmed that the tucatinib combination regimen can reduce the risk of disease progression in patients with brain metastases by approximately50%. In the breast cancer drug spectrum, this is one of the very few oral targeted drugs that can bring significant benefits to brain metastasis.

2. Prolong patient overall survival

Research results show that the median overall survival of patients using the tucatinib regimen is approximately 9 months longer than that of the control group. This is of great significance to patients who have received multiple lines of treatment and whose quality of life has been severely affected.

3. Good safety and tolerability

Although tucatinib may cause adverse reactions such as diarrhea, hand-foot syndrome, or abnormal liver function, it is generally controllable. Most patients can continue treatment through dose adjustment or symptomatic treatment, and the discontinuation rate is relatively low.

3. Analysis of price status and accessibility of tucatinib

1. Domestic market situation

At present, the original drug of tucatinib has not yet been launched in China and therefore cannot be included in medical insurance reimbursement. If domestic patients need medication, they mainly rely on overseas channels to purchase it.

2. European market price

According to public information, 150mg*84 tablets of the European version of the original drug Tucatinib may be sold for more than 4 RMB / box, which is a heavy burden for ordinary families.

3. Selection of overseas generic drugs

In some overseas markets, generic drugs have been launched. For example, the price of 150mg*60 tablets produced by a Lao pharmaceutical factory is about 2000 yuan. Compared with the original drug, the price is significantly lower, and the ingredients of the drug are basically the same, giving more patients the opportunity to receive treatment.

4. Medical insurance coverage

Because it is not marketed in the country, tucatinib is not yet included in medical insurance. The financial pressure on patients from long-term use is greater. At present, some patients choose to purchase products overseas, but there are potential risks of channel compliance and drug authenticity, so they need to be extra cautious.

4. Comparison between tucatinib and otherHER2 drugs

In the treatment ofHER2positive breast cancer, there are drugs such as trastuzumab, pertuzumab, T-DM1 and the popular T-DXd (Enhertu) in recent years. Compare to these drugs:

Trastuzumab and pertuzumab: the first choice for early treatment, but it is difficult to cover the needs of patients with brain metastases.

T-DM1: Suitable for second-line treatment, but some patients lack options after drug resistance.

T-DXd: Emerging ADC drug with remarkable efficacy, but high price and side effects that cannot be ignored.

Tucatinib: Orally administered, can penetrate the blood-brain barrier, and has unique efficacy in patients with brain metastases.

This comparison highlights the unique clinical value of tucatinib in a unique patient population.

5. Patient needs and future prospects

Urgent clinical needs: Tucatinib is undoubtedly a "life-saving drug" for HER2-positive patients with brain metastasis.

Prospects for listing: If it can be approved for listing in the country as soon as possible and entered into medical insurance, it will greatly reduce the burden on patients.

Trends in generic drugs: With the strengthening of cooperation between international pharmaceutical companies and local Chinese pharmaceutical companies, domestic generic versions of tucatinib may become available in the future, thus significantly reducing prices.

Development of precision medicine: With the popularization of molecular testing, more patients can be clearly suitable for tucatinib through genetic testing, thereby improving survival rates.

Tucatinib was introduced asHER2Positive breast cancer, especially in patients with brain metastases, offers new hope. Its efficacy has been confirmed by a number of authoritative clinical trials, but its high price and the fact that it has not yet been launched in China make it still difficult for patients to obtain it. In the future, with the advancement of more international cooperation and medical insurance policies, tucatinib is expected to benefit more Chinese patients at a more affordable price.

Frequently Asked QuestionsFAQ

Q1: Which breast cancer patients is tucatinib suitable for?

Mainly applicable to HER2 metastatic breast cancer patients who are positive and have received multiple lines of treatment, especially those with brain metastasis.

Q2: Are the adverse reactions of tucatinib serious?

Common side effects include diarrhea, liver function abnormalities, and hand-foot syndrome, which are usually manageable.

Q3: Can tucatinib be purchased in China?

At present, the original drugs are not yet on the market in China. Some overseas generic drugs can be obtained through formal channels, but you need to pay attention to the risks of authenticity.

Q4: Will tucatinib be included in medical insurance?

There is no clear news yet, but with increasing clinical demand and policy push, there is a possibility in the future.

xa0

References

1.Murthy RK, Loi S, Okines A, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020.

2.ASCO Annual Meeting 2023, HER2CLIMB Updated Results.

3.ESMO 2023 Highlights in HER2-positive Breast Cancer.

4.European Medicines Agency (EMA) Drug database.